PL3820874T3 - Selektywne środki degradujące receptor estrogenowy - Google Patents

Selektywne środki degradujące receptor estrogenowy

Info

Publication number
PL3820874T3
PL3820874T3 PL19746252.6T PL19746252T PL3820874T3 PL 3820874 T3 PL3820874 T3 PL 3820874T3 PL 19746252 T PL19746252 T PL 19746252T PL 3820874 T3 PL3820874 T3 PL 3820874T3
Authority
PL
Poland
Prior art keywords
degrade
estrogen receptor
selective agents
selective
agents
Prior art date
Application number
PL19746252.6T
Other languages
English (en)
Inventor
Jeffrey Daniel Cohen
Daniel Jon Sall
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67480324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3820874(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL3820874T3 publication Critical patent/PL3820874T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
  • Finger-Pressure Massage (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
PL19746252.6T 2018-07-12 2019-07-11 Selektywne środki degradujące receptor estrogenowy PL3820874T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862697100P 2018-07-12 2018-07-12
US201962825172P 2019-03-28 2019-03-28
PCT/US2019/041342 WO2020014440A1 (en) 2018-07-12 2019-07-11 Selective estrogen receptor degraders

Publications (1)

Publication Number Publication Date
PL3820874T3 true PL3820874T3 (pl) 2023-02-06

Family

ID=67480324

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19746252.6T PL3820874T3 (pl) 2018-07-12 2019-07-11 Selektywne środki degradujące receptor estrogenowy

Country Status (33)

Country Link
US (1) US12128040B2 (pl)
EP (1) EP3820874B1 (pl)
JP (1) JP7085056B2 (pl)
KR (1) KR102577142B1 (pl)
CN (1) CN112424205B (pl)
AU (1) AU2019299952B2 (pl)
BR (1) BR112020025381A2 (pl)
CA (1) CA3105491C (pl)
CL (1) CL2021000046A1 (pl)
CO (1) CO2021000041A2 (pl)
CR (1) CR20210006A (pl)
DK (1) DK3820874T3 (pl)
EC (1) ECSP21001786A (pl)
ES (1) ES2932867T3 (pl)
FI (1) FI3820874T3 (pl)
HR (1) HRP20230080T1 (pl)
HU (1) HUE061032T2 (pl)
IL (1) IL279990B2 (pl)
JO (1) JOP20210004B1 (pl)
LT (1) LT3820874T (pl)
MD (1) MD3820874T2 (pl)
MX (1) MX2021000377A (pl)
MY (1) MY210254A (pl)
PE (1) PE20211245A1 (pl)
PH (1) PH12021550048A1 (pl)
PL (1) PL3820874T3 (pl)
PT (1) PT3820874T (pl)
RS (1) RS63876B1 (pl)
SA (1) SA521421006B1 (pl)
SG (1) SG11202100145YA (pl)
SI (1) SI3820874T1 (pl)
UA (1) UA125890C2 (pl)
WO (1) WO2020014440A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017059139A1 (en) 2015-10-01 2017-04-06 Olema Pharmaceuticals, Inc. TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS
AU2016374441B2 (en) 2015-12-17 2021-10-21 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
CN109153644B (zh) 2016-03-16 2022-10-21 H·李·莫菲特癌症中心研究有限公司 用以增强效应t细胞功能的针对cereblon的小分子
EP3820532A4 (en) 2018-07-11 2022-04-06 H. Lee Moffitt Cancer Center & Research Institute, Inc. DIMERE IMMUNOMODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
CA3144791A1 (en) 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
TWI894443B (zh) * 2021-03-16 2025-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
EP4361143A4 (en) * 2021-08-31 2025-05-28 Eisai R&D Management Co., Ltd. Process for the preparation of a monocyclic pyridine derivative
PE20241731A1 (es) * 2022-02-01 2024-08-19 Lilly Co Eli Procesos para la preparacion de degradadores selectivos del receptor de estrogeno
WO2024042157A1 (en) 2022-08-25 2024-02-29 Sanofi Novel substituted quinoline and tetrahydronaphthalene carboxylic acid derivatives and therapeutic uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5521214A (en) * 1995-01-25 1996-05-28 Eli Lilly And Company Methods of inhibiting environmental estrogens
JPH10204082A (ja) * 1996-10-25 1998-08-04 Eli Lilly & Co 選択的エストロゲンレセプターモジュレーターとしての活性を有する置換されたベンゾ［ｂ］チオフェン化合物
EP1395563B1 (en) * 2001-05-22 2006-03-29 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
US7329654B2 (en) * 2001-12-19 2008-02-12 Janssen Pharmaceutica N.V. Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
CA2482986A1 (en) * 2002-04-19 2003-10-30 Signal Pharmaceuticals, Inc. Benzopyranone compounds, compositions thereof, and methods of treatment therewith
DE20301728U1 (de) * 2002-10-11 2004-03-11 Ligand Pharmaceuticals, Inc., San Diego 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
CL2004000985A1 (es) * 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
EA012262B1 (ru) 2004-01-22 2009-08-28 Эли Лилли Энд Компани Селективные модуляторы рецепторов эстрогена для лечения вазомоторных симптомов
JP2008512458A (ja) * 2004-09-07 2008-04-24 ワイス ６Ｈ−［１］ベンゾピラノ［４，３−ｂ］キノリン及びエストロゲン様物質としてのそれらの使用
US20080221163A1 (en) * 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
WO2016097071A1 (en) * 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
JP6768711B2 (ja) * 2015-05-26 2020-10-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 複素環式エストロゲン受容体モジュレーター及びその使用
EP3440067B1 (en) * 2016-04-08 2021-05-26 F. Hoffmann-La Roche AG Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
JP7229162B2 (ja) * 2017-01-06 2023-02-27 ジー１ セラピューティクス， インコーポレイテッド 癌の治療に対する併用療法
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑

Also Published As

Publication number Publication date
LT3820874T (lt) 2023-02-10
CA3105491C (en) 2023-09-05
DK3820874T3 (da) 2022-12-12
JOP20210004A1 (ar) 2021-01-10
JP7085056B2 (ja) 2022-06-15
MY210254A (en) 2025-09-04
IL279990B1 (en) 2023-03-01
US12128040B2 (en) 2024-10-29
WO2020014440A1 (en) 2020-01-16
RS63876B1 (sr) 2023-02-28
JOP20210004B1 (ar) 2024-04-18
US20210260052A1 (en) 2021-08-26
KR102577142B1 (ko) 2023-09-12
EP3820874B1 (en) 2022-11-30
CN112424205A (zh) 2021-02-26
IL279990A (en) 2021-03-01
FI3820874T3 (fi) 2023-03-06
CL2021000046A1 (es) 2021-06-25
HUE061032T2 (hu) 2023-05-28
EP3820874A1 (en) 2021-05-19
AU2019299952A1 (en) 2021-01-21
ES2932867T3 (es) 2023-01-27
NZ771719A (en) 2024-02-23
JP2021530486A (ja) 2021-11-11
PT3820874T (pt) 2023-01-06
MX2021000377A (es) 2021-03-25
AU2019299952B2 (en) 2022-06-16
UA125890C2 (uk) 2022-06-29
HRP20230080T1 (hr) 2023-03-17
IL279990B2 (en) 2023-07-01
KR20210018460A (ko) 2021-02-17
SI3820874T1 (sl) 2023-02-28
ECSP21001786A (es) 2021-02-26
CO2021000041A2 (es) 2021-01-18
SG11202100145YA (en) 2021-02-25
SA521421006B1 (ar) 2023-02-08
BR112020025381A2 (pt) 2021-03-09
CR20210006A (es) 2021-02-05
PH12021550048A1 (en) 2021-09-20
MD3820874T2 (ro) 2023-05-31
PE20211245A1 (es) 2021-07-13
CA3105491A1 (en) 2020-01-16
CN112424205B (zh) 2023-10-31

Similar Documents

Publication Publication Date Title
DK3820873T3 (da) Selektive østrogenreceptornedbrydere
EP3860183A4 (en) RELAY DEVICE
IL273830B2 (en) Aeroponics apparatus
EP3630078A4 (en) CHEMOEMBOLIZING AGENTS
DK3820874T3 (da) Selektive estrogenreceptornedbrydere
EP3763567A4 (en) SEAT
EP3801134A4 (en) SEAT ARRANGEMENT
EP3812318C0 (en) MATERIAL INTEGRATION DEVICE
DK3746678T3 (da) Fastspændingsindretning
EP3851001A4 (en) MIXER
EP3855992C0 (en) MIXER
EP3999191C0 (en) Harnesses
EP3742606A4 (en) MIXER
EP3914379C0 (de) Mischvorrichtung
EP3811824A4 (en) SEAT
EP3794588A4 (en) RELAY DEVICE
SI3880720T1 (sl) Osidijsko dispergirno sredstvo
DE112019000984A5 (de) Mischeinrichtung
EP3855083A4 (en) Relaying unit
PL4076108T3 (pl) Urządzenie mieszające
EP3849567A4 (en) ESTROGEN RECEPTOR TARGETED ANTAGONISTS
HUE061911T2 (hu) Olvadókészülék
PL3530106T3 (pl) Supłacz
EP3845103C0 (fr) Dispositif melangeur
IT201900023247A1 (it) Dispositivo di seduta